AI Engines For more Details: Perplexity Kagi Labs You
Major Depressive Disorder (MDD): Nefazodone hydrochloride is indicated for the treatment of major depressive disorder, a mood disorder characterized by persistent feelings of sadness, hopelessness, and a loss of interest in activities. It works by blocking the reuptake of serotonin and norepinephrine, thereby increasing the levels of these neurotransmitters in the brain, which can help alleviate symptoms of depression.
Anxiety Disorders: While nefazodone hydrochloride is primarily used for depression, it may also be prescribed off-label for the treatment of anxiety disorders, such as generalized anxiety disorder (GAD) and social anxiety disorder (SAD). Its effects on serotonin and norepinephrine levels in the brain may help reduce symptoms of anxiety in some individuals.
Insomnia: Some individuals with depression may experience insomnia or other sleep disturbances. Nefazodone hydrochloride may have sedative effects, which can help improve sleep quality in these individuals. However, it is not typically used as a first-line treatment for insomnia.
Pain Disorders: There is some evidence to suggest that nefazodone hydrochloride may be effective in the treatment of certain pain disorders, such as neuropathic pain and fibromyalgia. Its effects on serotonin and norepinephrine levels may modulate pain perception and provide relief in some individuals.
Obsessive-Compulsive Disorder (OCD): Nefazodone hydrochloride may be used off-label in the treatment of obsessive-compulsive disorder (OCD), a mental health condition characterized by repetitive thoughts (obsessions) and repetitive behaviors (compulsions). Its effects on serotonin levels in the brain may help reduce OCD symptoms in some individuals.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.6 | 0.4 | 0.5 |
| ADHD | 4.3 | 0.6 | 6.17 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2.6 | 0.31 |
| Allergies | 6 | 3.5 | 0.71 |
| Allergy to milk products | 2 | 1.6 | 0.25 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.4 | 6.6 | -0.03 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.7 | 1 | 2.7 |
| Ankylosing spondylitis | 4.8 | 1.2 | 3 |
| Anorexia Nervosa | 1.3 | 2.6 | -1 |
| Antiphospholipid syndrome (APS) | 1.9 | 1.9 | |
| Asthma | 4.7 | 3.3 | 0.42 |
| Atherosclerosis | 2.1 | 3 | -0.43 |
| Atrial fibrillation | 3.5 | 2.8 | 0.25 |
| Autism | 9.8 | 9.6 | 0.02 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.2 | 2.2 | |
| Bipolar Disorder | 1.8 | 1.4 | 0.29 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.9 | 2.1 | -1.33 |
| Carcinoma | 4 | 2.3 | 0.74 |
| Celiac Disease | 3.3 | 2.9 | 0.14 |
| Cerebral Palsy | 1.8 | 1 | 0.8 |
| Chronic Fatigue Syndrome | 4.6 | 6.1 | -0.33 |
| Chronic Kidney Disease | 4.5 | 2.3 | 0.96 |
| Chronic Lyme | 0.5 | 0.8 | -0.6 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.2 | 1.7 | 0.29 |
| Chronic Urticaria (Hives) | 1.7 | 1.8 | -0.06 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 1 | 0.7 |
| Cognitive Function | 3 | 1.6 | 0.88 |
| Colorectal Cancer | 7.5 | 2.6 | 1.88 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 2.4 | 3 | -0.25 |
| COVID-19 | 9.5 | 12.2 | -0.28 |
| Crohn's Disease | 9.1 | 5.7 | 0.6 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1 | 1.8 | -0.8 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 3.2 | 1.1 | 1.91 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 10.9 | 9.7 | 0.12 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.1 | 0.1 |
| Endometriosis | 3.3 | 1.8 | 0.83 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4 | 2.7 | 0.48 |
| erectile dysfunction | 2.6 | 0.3 | 7.67 |
| Fibromyalgia | 3.6 | 2.6 | 0.38 |
| Functional constipation / chronic idiopathic constipation | 5.6 | 4.1 | 0.37 |
| gallstone disease (gsd) | 3.8 | 1.6 | 1.37 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 0.6 | 2.33 |
| Generalized anxiety disorder | 3.6 | 2 | 0.8 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.6 | 1 | 0.6 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.4 | 0.3 | 3.67 |
| Hashimoto's thyroiditis | 3.6 | 1.1 | 2.27 |
| Heart Failure | 3.7 | 2 | 0.85 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.5 | 0.3 | 4 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.6 | 0.5 |
| hyperglycemia | 2 | 2.2 | -0.1 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.6 | 5.1 | -0.11 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 3.6 | 0.9 | 3 |
| IgA nephropathy (IgAN) | 1.6 | 4.6 | -1.87 |
| Inflammatory Bowel Disease | 9.1 | 8.9 | 0.02 |
| Insomnia | 2.1 | 2.9 | -0.38 |
| Intelligence | 1.7 | 0.6 | 1.83 |
| Intracranial aneurysms | 1.1 | 0.6 | 0.83 |
| Irritable Bowel Syndrome | 7.8 | 5.8 | 0.34 |
| ischemic stroke | 2.7 | 1.7 | 0.59 |
| Liver Cirrhosis | 7.6 | 5.1 | 0.49 |
| Long COVID | 8 | 6 | 0.33 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.2 | 1.3 | -0.08 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.1 | 0.6 | 0.83 |
| ME/CFS with IBS | 0.7 | 1.7 | -1.43 |
| ME/CFS without IBS | 1.5 | 2 | -0.33 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.6 | 1 | 0.6 |
| Metabolic Syndrome | 7.7 | 8.4 | -0.09 |
| Mood Disorders | 10.5 | 7.6 | 0.38 |
| multiple chemical sensitivity [MCS] | 1.3 | 0.1 | 12 |
| Multiple Sclerosis | 6.4 | 5.4 | 0.19 |
| Multiple system atrophy (MSA) | 2.1 | 0.4 | 4.25 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.3 | -10 |
| Neuropathy (all types) | 1.2 | 2.2 | -0.83 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.7 | 4.5 | 0.27 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 10.5 | 8.6 | 0.22 |
| obsessive-compulsive disorder | 5.4 | 4.3 | 0.26 |
| Osteoarthritis | 3.3 | 1.3 | 1.54 |
| Osteoporosis | 2.2 | 1.9 | 0.16 |
| pancreatic cancer | 0.8 | 0.3 | 1.67 |
| Parkinson's Disease | 7.8 | 7.5 | 0.04 |
| Polycystic ovary syndrome | 6.6 | 2.5 | 1.64 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 2.5 | 2.6 | -0.04 |
| Psoriasis | 3.1 | 4 | -0.29 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.5 | 4.7 | 0.38 |
| Rosacea | 0.4 | 0.7 | -0.75 |
| Schizophrenia | 5.8 | 2.9 | 1 |
| scoliosis | 0.7 | 0.7 | |
| Sjögren syndrome | 2.9 | 3.1 | -0.07 |
| Sleep Apnea | 1.6 | 1.5 | 0.07 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 0.2 | 9 |
| Stress / posttraumatic stress disorder | 3.5 | 2.9 | 0.21 |
| Systemic Lupus Erythematosus | 4.6 | 1.7 | 1.71 |
| Tic Disorder | 1.2 | 1.8 | -0.5 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 4.5 | 3.3 | 0.36 |
| Type 2 Diabetes | 8.8 | 8.4 | 0.05 |
| Ulcerative colitis | 5.8 | 8.1 | -0.4 |
| Unhealthy Ageing | 5 | 2.9 | 0.72 |
| Vitiligo | 1.9 | 2 | -0.05 |
